Surface profiles for subclassification of chronic lymphocytic leukemia

References

• Kay NE, Jelinek DF. B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood 2002;100:1110–1111.
   PubMedGoogle Scholar
• Rai KR, Sawitsky A, Cronkite EP, . Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Lepoprier M, Dighiero G, . A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855–864.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, . A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, . ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, . ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–111.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, . ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Bone ND, . CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008;140:537–546.
   PubMed Web of Science ®Google Scholar
• Hamblin T. Prognostic factors in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2261–2262.
   PubMed Web of Science ®Google Scholar
• Belov L, Huang P, Barber N, . Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003;3:2147–2154.
   PubMed Web of Science ®Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, . The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640–1645.
   PubMed Web of Science ®Google Scholar
• Matutes E, Attygalle A, Wotherspoon A, . Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:3–20.
   PubMed Web of Science ®Google Scholar
• Belov L, Mulligan SP, Barber N, . Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 2006;135:184–197.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, . CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146–2155.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, . In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135–1144.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Penther D, Avet-Loiseau H, . CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116:142–150.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Musto P, Cascavilla N, . CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42: 109–114.
   PubMed Web of Science ®Google Scholar
• Durig J, Naschar M, Schmucker U, . CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16:30–35.
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Stella S, . The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262–1269.
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Keating M, Do KA, . CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181–186.
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Dignum H, Taylor PR, . Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 2002;118:755–761.
   PubMed Web of Science ®Google Scholar
• Boonstra JG, von't Veer MB, Gratama JW. The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. J Biol Regul Homeost Agents 2004;18:340–346.
   PubMed Web of Science ®Google Scholar
• Matrai Z. CD38 as a prognostic marker in CLL. Hematology 2005;10:39–46.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Nunziata G, Coppola G, . CD38 expression does not change in B-cell chronic lymphocytic leukemia. Blood 2002; 100:3052–3053.
   PubMed Web of Science ®Google Scholar
• Eisele L, Haddad T, Sellmann L, . Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. Leuk Res 2009;33:775–778.
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, . Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750–758.
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Rubenzer G, Holler C, . Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006;108:2950–2956.
   PubMed Web of Science ®Google Scholar
• Abousamra NK, El-Din MS, Azmy E. T-cell CD38 expression in B-chronic lymphocytic leukaemia. Hematol Oncol 2009;27:82–89.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, . CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012–4021.
   PubMed Web of Science ®Google Scholar
• Patten PE, Buggins AG, Richards J, . CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173–5181.
   PubMed Web of Science ®Google Scholar
• Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev 2002;186:118–124.
   PubMed Web of Science ®Google Scholar
• de la Fuente MT, Casanova B, Garcia-Gila M, . Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266–274.
   PubMed Web of Science ®Google Scholar
• de la Fuente MT, Casanova B, Moyano JV, . Engagement of alpha 4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002;71:495–502.
   PubMed Web of Science ®Google Scholar
• Eksioglu-Demiralp E, Alpdogan O, Aktan M, . Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 1996;10:1331–1339.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zucchetto A, Rossi FM, . CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008;93:1575–1579.
   PubMed Web of Science ®Google Scholar
• Gattei V, Bulian P, Del Principe MI, . Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865–873.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Switala M, Collins CH, . High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 2009;131:472–480.
   PubMed Web of Science ®Google Scholar
• Majid A, Lin TT, Best G, . CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011;35:750–756.
   PubMed Web of Science ®Google Scholar
• Kumpfel T, Heydari N, Hohlfeld R. Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis. Nervenarzt 2002;73:552–555.
   PubMed Web of Science ®Google Scholar
• Mraz M, Zent CS, Church AK, . Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011;155:53–64.
   PubMed Web of Science ®Google Scholar
• Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol 2002;68:127–134.
   PubMed Web of Science ®Google Scholar
• Nakase K, Kita K, Nasu K, . Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 1994;46:179–183.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Bartholmai BJ, Witzig TE, . Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997;95:173–177.
   PubMed Web of Science ®Google Scholar
• Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994;8:92–96.
   PubMed Web of Science ®Google Scholar
• Sulda ML, Kuss BJ, Hall RK, . The clinical utility of molecular and flow cytometric markers in CLL. Intern Med J 2010 Jun 15. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Capello D, Zucchetto A, Degan M, . Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 2006;30:1197–1199.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Sonego P, Degan M, . Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. J Cell Physiol 2005;204:113–123.
   PubMed Web of Science ®Google Scholar
• Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249–264.
   PubMed Web of Science ®Google Scholar
• Buhling F, Junker U, Reinhold D, . Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47–51.
   PubMed Web of Science ®Google Scholar
• Iwata S, Morimoto C. CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 1999;190:301–306.
   PubMed Web of Science ®Google Scholar
• Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004;19:1345–1351.
   PubMed Web of Science ®Google Scholar
• Cro L, Morabito F, Zucal N, . CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol 2009;27:140–147.
   PubMed Web of Science ®Google Scholar
• Kamoun M, Martin PJ, Hansen JA, . Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med 1981;153:207–212.
   PubMed Web of Science ®Google Scholar
• Cantu-Rajnoldi A, Putti MC, Schiro R, . Biological and clinical features of B-precursor childhood acute lymphoblastic leukemia showing CD2 and/or E-rosette co-expression. Haematologica 1992;77:384–391.
   PubMed Web of Science ®Google Scholar
• Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Am J Hematol 1996;52: 224–226.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Muraguchi A, Ledbetter JA, . Biphenotypic leukemic lymphocyte precursors in CD2 + CD19 + acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 1989;73:1000–1015.
   PubMed Web of Science ®Google Scholar
• Ahmad E, Steinberg SM, Goldin L, . Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008;74:221–226.
   PubMed Web of Science ®Google Scholar
• Brohee D, Cauchie P, Neve P. Co-expression of CD2 or CD8 antigens in B-cell chronic lymphocytic leukaemia. A flow cytometry analysis of 3 cases. Acta Clin Belg 1994;49:183–186.
   PubMed Web of Science ®Google Scholar
• Kingma DW, Imus P, Xie XY, . CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms. Cytometry 2002;50:243–248.
   PubMedGoogle Scholar
• Viciana AL, Lancet FC, Chamizo W, . Simultaneous expression of CD2 on a B-cell, small lymphocytic neoplasm. Cytometry 1994;18:42–48.
   PubMedGoogle Scholar
• Matutes E, Wechsler A, Gomez R, . Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br J Haematol 1981;49:635–642.
   PubMed Web of Science ®Google Scholar
• Kurec AS, Threatte GA, Gottlieb AJ, . Immunophenotypic subclassification of chronic lymphocytic leukaemia (CLL). Br J Haematol 1992;81:45–51.
   PubMed Web of Science ®Google Scholar
• Newman RA, Peterson B, Davey FR, . Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1993;82:1239–1246.
   PubMed Web of Science ®Google Scholar
• Kampalath B, Barcos MP, Stewart C. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2003;119:824–832.
   PubMed Web of Science ®Google Scholar
• Avila-Carino J, Lewin N, Tomita Y, . B-CLL cells with unusual properties. Int J Cancer 1997;70:1–8.
   PubMed Web of Science ®Google Scholar
• Carulli G, Stacchini A, Marini A, . Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: a multicenter study of 951 bone marrow samples with lymphomatous infiltration. Am J Clin Pathol 2009;132:186–190; quiz 306.
   PubMed Web of Science ®Google Scholar
• Espinosa A, Bjork P, Magnussen K, . Aberrant expression of the CD8 antigen in B cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:193–196.
   PubMed Web of Science ®Google Scholar
• Fernhout F, Dinkelaar RB, Hagemeijer A, . Four aged siblings with B cell chronic lymphocytic leukemia. Leukemia 1997;11:2060–2065.
   PubMed Web of Science ®Google Scholar
• Islam A, Vladutiu AO, Donahue T, . CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature. Arch Pathol Lab Med 2000;124:1361–1363.
   PubMed Web of Science ®Google Scholar
• Kaleem Z, White G, Zutter MM. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001;115:396–403.
   PubMed Web of Science ®Google Scholar
• Mulligan SP, Dao LP, Francis SE, . B-cell chronic lymphocytic leukaemia with CD8 expression: report of 10 cases and immunochemical analysis of the CD8 antigen. Br J Haematol 1998;103:157–162.
   PubMed Web of Science ®Google Scholar
• Parisi-Duchene E, Mazurier I, Moskovtchenko P. Aberrant CD8 expression in B-chronic lymphocytic leukemia: report of five cases. Acta Haematol 2006;115:74–77.
   PubMed Web of Science ®Google Scholar
• Schroers R, Pukrop T, Durig J, . B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. Leuk Lymphoma 2004;45:1677–1681.
   PubMed Web of Science ®Google Scholar
• Stagno F, Triolo A, Del Fabro V, . Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells. Lab Hematol 2009;15:1–3.
   PubMedGoogle Scholar
• Attadia V, Alosi M, Improta S, . Immunophenotypic and molecular genetic characterization of a case of CD8 + B cell chronic lymphocytic leukemia. Leukemia 1996;10:1544–1550.
   PubMed Web of Science ®Google Scholar
• Brunet C, Bardin N, Oukhouya O, . A case report: CD8 expression in B-cell chronic lymphocytic leukemia (B-CLL). Prognostic significance of the aberrant CD8 expression. Hematol Cell Ther 1998;40:279–282.
   PubMedGoogle Scholar
• Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, . Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1829–1836.
   PubMed Web of Science ®Google Scholar
• Paul P, Cabestre FA, Ibrahim EC, . Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000;61:1138–1149.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Rebmann V, Durig J, . HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005;105:1694–1698.
   PubMed Web of Science ®Google Scholar
• Erikci AA, Karagoz B, Ozyurt M, . HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 2009;14:101–105.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Honjo T. Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol 2001;2:493–503.
   PubMed Web of Science ®Google Scholar
• Heintel D, Kroemer E, Kienle D, . High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004;18:756–762.
   PubMed Web of Science ®Google Scholar
• McCarthy H, Wierda WG, Barron LL, . High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 2003;101:4903–4908.
   PubMed Web of Science ®Google Scholar
• Palacios F, Moreno P, Morande P, . High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 2010;115:4488–4496.
   PubMed Web of Science ®Google Scholar
• Meyaard L, Adema GJ, Chang C, . LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997;7:283–290.
   PubMed Web of Science ®Google Scholar
• Poggi A, Catellani S, Bruzzone A, . Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008;22:980–988.
   PubMed Web of Science ®Google Scholar
• Alatrash G, Albitar M, O’Brien S, . Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148:386–393.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010;23:133–143.
   PubMed Web of Science ®Google Scholar
• Barclay AN, Wright GJ, Brooke G, . CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002;23:285–290.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4 + CD25 + Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:1180–1183.
   PubMed Web of Science ®Google Scholar
• Tonks A, Hills R, White P, . CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566–568.
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Ulbrich S, Brinker R, . Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009;33:460–464.
   PubMed Web of Science ®Google Scholar
• Wong KK, Khatri I, Shaha S, . The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010;88:361–372.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol Rev 2003;195:58–71.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.
   PubMed Web of Science ®Google Scholar
• Burkle A, Niedermeier M, Schmitt-Graff A, . Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316–3325.
   PubMed Web of Science ®Google Scholar
• Kipps T. Chronic lymphocytic leukemia and related disorders. In: Beutler E, Lichtman MA, Coller BS, , editors. William's hematology. New York: McGraw-Hill; 1995. p 1017.
   Google Scholar
• Zupo S, Massara R, Dono M, . Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000;95:1199–1206.
   PubMed Web of Science ®Google Scholar
• Kim KM, Reth M. Signaling difference between class IgM and IgD antigen receptors. Ann NY Acad Sci 1995;766:81–88.
   PubMed Web of Science ®Google Scholar
• Cutrona G, Colombo M, Matis S, . Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica 2008;93:413–422.
   PubMed Web of Science ®Google Scholar
• Herve M, Xu K, Ng YS, . Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005;115:1636–1643.
   PubMed Web of Science ®Google Scholar
• Ligler FS, Kettman JR, Smith RG, . Immunoglobulin phenotype on B cells correlates with clinical stage of chronic lymphocytic leukemia. Blood 1983;62:256–263.
   PubMed Web of Science ®Google Scholar
• Shen PU, Fuller SG, Rezuke WN, . Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001;116:905–912.
   PubMed Web of Science ®Google Scholar
• Bojarska-Junak A, Hus I, Sieklucka M, . Natural killer-like T CD3 + /CD16 + CD56 + cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol Rep 2010;24:803–810.
   PubMed Web of Science ®Google Scholar
• Damle RN, Ghiotto F, Valetto A, . B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087–4093.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Quijano S, Lopez A, Rasillo A, . Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008;74:139–149.
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Vilpo L, Hurme M, . Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia 2002;16:178–185.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Bomben R, Dal Bo M, . A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol 2006;207:354–363.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Sonego P, Degan M, . Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. J Transl Med 2006;4:11.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Sonego P, Degan M, . Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): identification of markers with prognostic relevance. J Immunol Methods 2005;305:20–32.
   PubMed Web of Science ®Google Scholar
• Hjalmar V, Kimby E, Matutes E, . Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. Haematologica 1998;83:602–609.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier D, Gahrton G; for the International Working Party on Chromosomes in CLL (IWCCLL). Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 622 patients. Leuk Lymphoma 1991;5:21–25.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Stewart G, . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814–822.
   PubMed Web of Science ®Google Scholar
• Zenz T, Frohling S, Mertens D, . Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71–84.
   PubMed Web of Science ®Google Scholar
• Eisele L, Prinz R, Klein-Hitpass L, . Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 2009;83:320–327.
   PubMed Web of Science ®Google Scholar
• Friedrichs B, Siegel S, Reimer R, . High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. Leuk Res 2011;35:721–729.
   PubMed Web of Science ®Google Scholar
• Mansouri M, Sevov M, Fahlgren E, . Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res 2010;34:301–306.
   PubMed Web of Science ®Google Scholar
• Kotaskova J, Tichy B, Trbusek M, . High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn 2010;12:328–334.
   PubMed Web of Science ®Google Scholar
• Li S, Moffett HF, Lu J, . MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One 2011;6:e16956.
   PubMed Web of Science ®Google Scholar
• Penna G, Allegra A, Alonci A, . MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 2010 May 22. [Epub ahead of print]
   Web of Science ®Google Scholar
• Zhu HJ, Xu W, Cao X, . Detection of PUMA mRNA levels by real-time quantitative RT-PCR in chronic lymphocytic leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18: 843–848.
   PubMedGoogle Scholar
• Josefsson P, Geisler CH, Leffers H, . CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007;109:4973–4979.
   PubMed Web of Science ®Google Scholar
• Hassanein NM, Perkinson KR, Alcancia F, . A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. Am J Clin Pathol 2010;133:708–717.
   PubMed Web of Science ®Google Scholar
• Gentile M, Mauro FR, Calabrese E, . The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549–557.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Fernandez C, Giustolisi GM, . CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004;5:145–151.
   PubMedGoogle Scholar
• Hsi ED, Kopecky KJ, Appelbaum FR, . Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2003;120:1017–1025.
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G, Venditti A, . Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica 2004;89:1468–1475.
   PubMed Web of Science ®Google Scholar
• Hus I, Podhorecka M, Bojarska-Junak A, . The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17:683–690.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Tarnani M, Rumi C, . Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol 2007;82:787–791.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Schnittger S, . Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442–2451.
   PubMed Web of Science ®Google Scholar
• Weinberg JB, Volkheimer AD, Chen Y, . Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007;82:1063–1070.
   PubMed Web of Science ®Google Scholar
• Hus I, Bojarska-Junak A, Dmoszynska A, . ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. Folia Histochem Cytobiol 2008; 46:147–152.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Jain S, Keating MJ, . Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112:1923–1930.
   PubMed Web of Science ®Google Scholar
• Xu W, Li JY, Wu YJ, . CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009;33:237–243.
   PubMed Web of Science ®Google Scholar
• Morabito F, Cutrona G, Gentile M, . Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009;146:44–53.
   PubMed Web of Science ®Google Scholar
• Hock BD, McKenzie JL, McArthur L, . CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data. Intern Med J 2010;40:842–849.
   PubMed Web of Science ®Google Scholar